NASDAQ:QGEN - Qiagen Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $37.75 +0.47 (+1.26 %) (As of 08/20/2018 10:25 AM ET)Previous Close$37.54Today's Range$37.54 - $37.7552-Week Range$30.20 - $39.18Volume20,877 shsAverage Volume976,691 shsMarket Capitalization$7.77 billionP/E RatioN/ADividend YieldN/ABeta0.98 Company ProfileAnalyst RatingsChartEarnings HistoryFinancialsHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight. Receive QGEN News and Ratings via Email Sign-up to receive the latest news and ratings for QGEN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryLife Sciences Tools & Services SectorN/A SymbolNASDAQ:QGEN CUSIPN7248210 Webwww.qiagen.com Phone+31-77-3556600 Debt Debt-to-Equity Ratio0.69 Current Ratio5.07 Quick Ratio4.59 Price-To-Earnings Trailing P/E RatioN/A Forward P/E Ratio28.17 P/E Growth1.93 Sales & Book Value Annual Sales$1.42 billion Price / Sales6.08 Cash Flow$2.7901 per share Price / Cash13.53 Book Value$11.13 per share Price / Book3.39 Profitability EPS (Most Recent Fiscal Year)N/A Net Income$40.39 million Net Margins2.85% Return on Equity11.74% Return on Assets6.28% Miscellaneous Employees4,684 Outstanding Shares228,230,000Market Cap$7.77 billion Qiagen (NASDAQ:QGEN) Frequently Asked Questions What is Qiagen's stock symbol? Qiagen trades on the NASDAQ under the ticker symbol "QGEN." How will Qiagen's stock buyback program work? Qiagen declared that its board has authorized a stock repurchase plan on Thursday, February 1st 2018, which permits the company to buyback $200,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to purchase shares of its stock through open market purchases. Shares buyback plans are generally a sign that the company's board of directors believes its shares are undervalued. How were Qiagen's earnings last quarter? Qiagen NV (NASDAQ:QGEN) released its earnings results on Tuesday, July, 31st. The company reported $0.33 EPS for the quarter, beating the consensus estimate of $0.32 by $0.01. The company had revenue of $377.20 million for the quarter, compared to analyst estimates of $376.89 million. Qiagen had a return on equity of 11.74% and a net margin of 2.85%. View Qiagen's Earnings History. When is Qiagen's next earnings date? Qiagen is scheduled to release their next quarterly earnings announcement on Monday, November, 5th 2018. View Earnings Estimates for Qiagen. What guidance has Qiagen issued on next quarter's earnings? Qiagen updated its FY18 earnings guidance on Tuesday, July, 31st. The company provided earnings per share (EPS) guidance of $1.31-1.33 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.34. The company issued revenue guidance of $1.50-1.52 billion (+6-7% CER), compared to the consensus revenue estimate of $1.54 billion.Qiagen also updated its Q3 guidance to $0.33-0.34 EPS. What price target have analysts set for QGEN? 11 brokerages have issued 1 year price objectives for Qiagen's shares. Their predictions range from $34.00 to $40.00. On average, they anticipate Qiagen's share price to reach $37.5714 in the next twelve months. This suggests that the stock has a possible downside of 0.5%. View Analyst Price Targets for Qiagen. What is the consensus analysts' recommendation for Qiagen? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Qiagen in the last year. There are currently 6 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Qiagen. Who are Qiagen's key executives? Qiagen's management team includes the folowing people: Manfred E. Karobath, Chairman of the Supervisory Board (Age 76)Peer M. Schatz, Chief Executive Officer, Managing DirectorRoland Sackers, Chief Financial OfficerThomas Schweins, Senior Vice President - Human Resources, Strategy & Marketing ServicesThierry Bernard, Senior Vice President - Molecular Diagnostics Business AreaLaura Furmanski, Senior Vice President - Bioinformatics Business AreaDouglas Liu, Senior Vice President - Global OperationsManuel O. Mendez, Senior Vice President - Global Commercial OperationsStephane Bancel, Independent Supervisory Director (Age 44)Hakan Bjorklund, Supervisory Board Director (Age 61) Has Qiagen been receiving favorable news coverage? Press coverage about QGEN stock has trended somewhat positive this week, Accern Sentiment reports. Accern scores the sentiment of press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Qiagen earned a media and rumor sentiment score of 0.21 on Accern's scale. They also gave news articles about the company an impact score of 46.23 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term. View Recent Headlines for Qiagen. Who are Qiagen's major shareholders? Qiagen's stock is owned by a number of of institutional and retail investors. Top institutional investors include Massachusetts Financial Services Co. MA (5.15%), BlackRock Inc. (2.71%), Hardman Johnston Global Advisors LLC (1.65%), Frontier Capital Management Co. LLC (1.09%), Legal & General Group Plc (0.92%) and First Trust Advisors LP (0.75%). Which institutional investors are selling Qiagen stock? QGEN stock was sold by a variety of institutional investors in the last quarter, including Manning & Napier Group LLC, Russell Investments Group Ltd., Millennium Management LLC, Systematic Financial Management LP, WINTON GROUP Ltd, Marshall Wace LLP, Legal & General Group Plc and Ontario Teachers Pension Plan Board. Which institutional investors are buying Qiagen stock? QGEN stock was acquired by a variety of institutional investors in the last quarter, including First Trust Advisors LP, OppenheimerFunds Inc., BlackRock Inc., RTW Investments LP, Assenagon Asset Management S.A., Sandler Capital Management, Morgan Stanley and Acadian Asset Management LLC. How do I buy shares of Qiagen? Shares of QGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Qiagen's stock price today? One share of QGEN stock can currently be purchased for approximately $37.75. How big of a company is Qiagen? Qiagen has a market capitalization of $7.77 billion and generates $1.42 billion in revenue each year. Qiagen employs 4,684 workers across the globe. How can I contact Qiagen? Qiagen's mailing address is Hulsterweg 82, VENLO, 5912 PL, Netherlands. The company can be reached via phone at +31-77-3556600 or via email at [email protected] MarketBeat Community Rating for Qiagen (NASDAQ QGEN)Community Ranking: 2.2 out of 5 ( )Outperform Votes: 315 (Vote Outperform)Underperform Votes: 417 (Vote Underperform)Total Votes: 732MarketBeat's community ratings are surveys of what our community members think about Qiagen and other stocks. Vote "Outperform" if you believe QGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe QGEN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 8/20/2018 by MarketBeat.com StaffFeatured Article: How do investors use RSI to grade stocks?